• Taligen Therapeutics Inc., of Cambridge, Mass., closed a $10 million tranche of its Series B round from existing investors Clarus Ventures, Alta Partners, Sanderling Ventures and High Country Ventures. Funding is expected to help the firm advance TT30, its lead candidate targeted to complement factor H protein, through the early stages of clinical development. TT30 is in development for inflammatory and autoimmune diseases. The company secured the $65 million Series B in February 2008, and the latest tranche brings the amount closed to date to $36 million. (See BioWorld Today, Feb. 4, 2008.)

• Warner Chilcott plc, of Ardee, Ireland, incurred an additional $1 .5 billion aggregate principal amount of new term loan through an amendment to its existing secured credit facilities. Proceeds will be used to help fund a special cash dividend to shareholders.